China FDA clears CStone to start trials of anti-PD-L1 mAb

CStone Pharmaceuticals Co. Ltd. (Shanghai, China) said China FDA has cleared the company to begin Chinese trials of CS1001 (formerly WBP3155), a recombinant mAb against PD-L1, to treat advanced cancers. The company hopes to develop CS1001 to treat cancers prevalent in China, including via combination therapies...